CAMBRIDGE, Mass. and HANGZHOU, China, Sept. 26, 2017 /PRNewswire/ -- 1CellBiO Inc., a leadingsingle-cell analysis company serving the biomedical research community, today announced that it has signed a reseller and license agreement with Hangzhou Chengyuan Genomics Company (Chengyuan), a premier life-science research and development start-up
Under the agreement, Chengyuan has agreed to provide single cell analysis research services to the rapidly growing biotechnology research customer base in China. In addition, Chengyuan will sell in that country the 1CellBiO inDropTM instrument for high-resolution single cell RNA sequencing, along with all of the kits and consumables needed to run the system.
"Hangzhou Chengyuan Genomics Company is a best-in-class partner with technical and informatics expertise and extensive reach across the fast-growing Chinese market. We are looking forward to working with them as we drive the adoption of our platform and transform single-cell analysis research around the world," stated Colin J.H. Brenan, Ph.D., Chief Executive Officer.
"Ultra-high throughput single cell analysis is one of the most exciting breakthroughs in life science over the last few years and will be a key driver for new discoveries for years to come. We are convinced that inDrop is truly the leading technology in this field, and we are honored to partner with 1CellBiO to market this technology in China," said Xi Chen, Ph.D., Chief Executive Officer of Chengyuan.
Terms of the agreement were not disclosed.
About 1CellBiO Inc
1CellBiO Inc. is a leading single-cell analysis company commercializing the open, flexible and cost-effective inDropTM instrument for single cell, high resolution whole transcriptome profiling with unparalleled data quality. The inDrop System and methods have seen rapid, global adoption with research laboratories eager to harness the power of single cell whole transcriptional profiling in a diversity of studies from stem cells to embryo development to the identification and validation of new drug targets. Learn more at www.1cell-bio.com.
About Hangzhou Chengyuan Genomics Company
Hangzhou Chengyuan Genomics Company is a Hangzhou, China-based biotechnology research and development company that offers cutting-edge research and development products and services in China. Combining the expertise in microfluidics, gene-editing, nucleic acid engineering and bioinformatics, Chengyuan serves as a one-stop shop for ultra-high throughput single cell analysis at genome scale, with applications in oncology, immunology, stem cell research, neurobiology and more. Chengyuan was founded in 2017 with investment from Nest.bio Ventures.
View original content:http://www.prnewswire.com/news-releases/1cellbio-signs-reseller-and-license-agreement-with-hangzhou-chengyuan-genomics-co-to-deliver-groundbreaking-single-cell-analysis-technology-to-china-300524593.html
SOURCE 1CellBiO Inc.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All